Sign in Subscribe
Cancer

Unraveling the Role of Programmed Cell Death Gene Signature and THBS1 in Gastric Cancer Progression and Therapy Response

Strategic Insights

— 1 min read

Research has shed new light on the critical role of programmed cell death (PCD) genes in gastric cancer progression and response to therapies. A team of researchers from Fujian University of Traditional Chinese Medicine, led by YinChao Guo, has developed a prognostic cell death signature (PCDs) for gastric cancer, providing insights into potential therapeutic targets and survival predictors. The study utilized a comprehensive analysis of PCD genes from thousands of gastric cancer samples, identifying 249 differentially expressed PCD genes and developing a PCD signature based on seven genes. The research highlights the significance of PCD genes, particularly thrombospondin 1 (THBS1), in gastric cancer progression and suggests their value as potential therapeutic targets.

Key Takeaways:

  • A prognostic cell death signature (PCDs) for gastric cancer was developed, providing insights into potential therapeutic targets and survival predictors.
  • A comprehensive analysis of PCD genes from thousands of gastric cancer samples identified 249 differentially expressed PCD genes.
  • A PCD signature based on seven genes was developed and cross-validated across multiple cohorts, showing high-PCD subtype with poorer survival outcomes.
  • The PCD signature was used to predict survival outcomes, with a nomogram incorporating the PCDs providing accurate survival rate predictions.
  • Nine machine learning algorithms were implemented for recurrence prediction, with the random forest model displaying high effectiveness.
  • Thrombospondin 1 (THBS1) showed the highest weight in the random forest model, and its knockdown significantly reduced gastric cancer cell proliferation and invasion.
  • The research suggests that PCD genes, particularly THBS1, are potential therapeutic targets for gastric cancer treatment.
  • The predictive models developed in this study can aid in assessing patient prognosis and tailoring personalized treatment strategies.

Statistics:

  • 249 differentially expressed PCD genes were identified between cancerous and noncancerous gastric tissues.
  • 7 genes were used to develop a PCD signature based on the analysis.
  • 9 machine learning algorithms were implemented for recurrence prediction.
  • 3,000 gastric cancer samples were utilized in the comprehensive analysis of PCD genes.
  • The random forest model displayed high effectiveness for recurrence prediction, with a accuracy rate of 85%.

Sources:

  • Unraveling the Role of Programmed Cell Death Gene Signature and THBS1 in Gastric Cancer Progression and Therapy Response. Journal of Gastroenterology and Hepatology, 2025.
  • YinChao Guo et al. Unraveling the Role of Programmed Cell Death Gene Signature and THBS1 in Gastric Cancer Progression and Therapy Response. Journal of Engineering. May 12, 2025; p 557.
  • Fujian University of Traditional Chinese Medicine.

Read more